Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Current clinical trials in pancreatic ductal adenocarcinoma immunotherapy
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current clinical trials in pancreatic ductal adenocarcinoma immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Clinical Trial
100%
Immunotherapy
100%
Pancreas Adenocarcinoma
100%
Survival Rate
40%
Monoclonal Antibody
20%
Overall Survival
20%
Side Effect
20%
Cancer Cell
20%
Early Diagnosis
20%
Solid Malignant Neoplasm
20%
Immune System
20%
Targeted Therapy
20%
Pancreas Cancer
20%
Emerging Treatment
20%
Immune Checkpoint Inhibitor
20%
Transfer Cell
20%
Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Immunotherapy
100%
Pancreas Adenocarcinoma
100%
Chemotherapy
40%
Survival Rate
40%
Monoclonal Antibody
20%
Malignant Neoplasm
20%
Side Effect
20%
Pancreas Cancer
20%
Solid Malignant Neoplasm
20%
Overall Survival
20%
Immune Checkpoint Inhibitor
20%
Keyphrases
Still Face
25%
Antibody Vaccines
25%
Immunology and Microbiology
Vaccine Therapy
20%